At Money Map Press, we value getting your questions about the service answered in a timely manner.
Feel free to search or browse for an answer to our most popular questions. Our customer service team is also available to answer any of your questions – simply fill out the form here, call our customer service team Monday through Friday from 8am to 5pm at 1-888-384-8339.
Money Map Press
1125 N Charles Street
How can we help you today?
A: Securities regulations and company policies prohibit us from offering that. But that doesn’t mean we won’t be thrilled to hear from you. However, if you have an idea for a column or a topic or question that you would like to see explored (especially topics you believe other readers will benefit from learning about), you can let us know your idea by contacting our customer service team. They will forward your message along to me.
A: In all of the advisory services marketed by Money Map Press – unless we specifically say something to the contrary – our experts recommend that investors employ a 25% “trailing stop” on all their holdings, including new buys. That holds true for Private Briefing, as well.
Here’s a typical example that demonstrates why.
During one of their daily briefings, Bill Patalon learned about New York-based oncology biotech Delcath Systems Inc. (Nasdaq: DCTH) . Once the guru described the company’s proprietary system for chemosaturation, which is designed to administer high-dose chemotherapy and other therapeutic agents directly into diseased organs… Bill wasted no time recommending the stock to his Private Briefing readers.
The shares ultimately soared as much as 46% in less than five months. Then liquidity concerns, a dilutive secondary offering, competitive worries and a lousy stock market combined to send the stock down by more than half from where it was originally recommended.
One subscriber admitted to having ridden the recommendation to a big gain – only to give back all the profits and then incur a big loss by not using protective stops.
But – and this is key – investors who did use the “trailing stop” strategies that our experts recommend could have exited with a 10% profit.
What’s more, once the stock finished its sell-off, insiders bought huge positions in the beaten-down stock. Because that’s one of our best “Buy” signals – and because we still liked the company’s strategy – we told subscribers about the insider buying and “re-recommended” the stock.
Less than a month later, the stock gained as much as 59% from its post-sell-off nadir – meaning subscribers who followed our entire strategy (buying when we recommended the stock, while protecting themselves with trailing stops) could have profited nicely from both surges in the shares.
A: It’s true: Private Briefing doesn’t issue real-time “Sell” recommendations. Instead, we have opted to give you the power to make as much money as you want from our recommendations.
Here’s what we mean.
Although Private Briefing has already recommended dozens of winners, we also recognize that individual investors have different goals. They also have different abilities to tolerate risk.
For instance, we know a more-aggressive investor might opt to stay invested, wishing to pursue even bigger gains, while a conservative investor might not want to run the risk of losing those same profits if the stock were to drop. At Private Briefing, we put the decision in your hands by offering you the necessary information to make the call.
There are other factors involved here, too.
Because our subscriber list grows so much over the course of the year, we recognize that investors bought in at many different price points. That, too, makes it difficult for us to issue “Sell” alerts.
In truth, “Sell” alerts are an added offering to our full-featured trading services here at Money Map Press.
It’s a tradeoff: We’re the only paid service here to offer daily news, analysis and recommendations to our subscribers. That means you get more communication and information with Private Briefing thank you do from any of the others.
In the end, we let you decide what’s right for you.
A: That’s a great question. The fact is, Money Map Press Publisher Bob Keppel made the decision to bring in the best talent available.
As we noted above, each of our experts runs one or more of their own advisory services. Plus, they also all collaborate on The Money Map Report, our monthly subscription-based newsletter.
One of our goals for Private Briefing is to deliver such great value that you’ll want to remain part of the Money Map Press “family.”
Perhaps then you’ll decide that you want more insights on technology – so you’ll keep Private Briefing, but also add tech guru Michael Robinson’s Radical Technology Profits.
Regardless, our goal is to help you maximize your personal wealth over the long term. You’ll find that the “Profit While You Learn” education that begins with Private Briefing continues – albeit at a much higher level – throughout our entire product family.
A: A Private Briefing subscription offers readers access to:
- Shah Gilani, a retired hedge-fund manager who at one time owned his own exchange seat.
- Michael Robinson, an author and former journalist who is one of the country’s leading experts on technology investing.
- Ernie Tremblay, a gifted researcher with 20 years’ experience tracking bioscience and pharma stocks who is a master of the FDA approval process.
Each of these experts runs one or more of their own advisory services. Plus, they also all collaborate on The Money Map Report, our monthly subscription-based newsletter.
A: Good question. And the answer is “yes.” Drawing upon the insights and recommendations of the experts throughout Money Map Press, Executive Editor Bill Patalon regularly creates special research reports for subscribers.
For instance, in “The Biotech Buyout Binge: Why these three stocks could double your money in the next 12 months,” Bill let his readers in on a way to make huge gains off a “patent cliff” crisis facing large Biopharma firms. One reader, Amy St. George, who played some of the companies featured in the report, wrote in to tell us,
“You were SPOT ON with ALL your biotech buyout recommendations! Keep ’em coming! I am currently holding CLDX at a 233.45% GAIN. And my biggest, PCYC is at 235.22% and COUNTING.”
A: Bill Patalon is an author and award-winning business-and-finance journalist with three decades of experience. He’s covered some of the biggest public companies around and has interviewed prominent executives and politicians including former GE CEO Jack Welch, former U.S. President Richard M. Nixon and presidential candidate Steve Forbes.
He is the co-author of the best-seller “Contrarian Investing: How to Buy and Sell When Others Won’t and Make Money Doing It,” which was published by Prentice Hall’s New York Institute of Finance arm back in 1998. Investing icon Jim Rogers wrote the foreword for the book on a request from Bill.
Frank Barisi wrote in to say: “I have turned a nice profit from Bill’s Private Briefing tips. Roughly 200% gain in just under half a year. I particularly like his concept of skimming the cream of the other analysts.”
F. Baumann told us: “I am up a little over 200% on Galena. This is just to say Bill, that there is no better investment letter out there anywhere!”
Tony Matalon said, “I am a subscriber of Private Briefing almost since the beginning and I’ve seen many triples and doubles on your recommendations. I must congratulate you and your team of experts on the excellent job you are doing.”
James Wohlers wrote saying: “On TSRX I’m up 98%, while on INO I’m up 134%. Keep up the good work. I love the tone of your writing and the stock picks you suggest are terrific.”
Margaret Weidmann-Scott told us: “Love your letter. First trade after joining your letter, I bought 2,000 shares of AMD for a gain of $2061.88. Very happy with the profit.”
A: Private Briefing is based on a carefully defined “value proposition.” That’s because it’s all about “access.” Here at Money Map Press, we market a number of sophisticated advisory services, some of which cost hundreds, or even thousands, of dollars a year.
Each day, Private Briefing gives subscribers access to some of the same thinking and trade recommendations put forth by such experts as Shah Gilani, Michael Robinson, and Ernie Tremblay.
The good news is that access comes at a greatly reduced cost. Private Briefing subscribers pay just $19.99 a month – just 66 cents a day – to access trading recommendations that would otherwise cost $36,046 to access.
Judging from the consistently terrific feedback we’re getting – as well as the low subscriber turnover – this overall approach has really resonated with our subscribers.
I read your promotional materials for Private Briefing, and like what I see. You have an ambitious agenda and made some significant promises. Are you delivering on those product promises?
A: We’ve been doing our best since day one, and we believe we’re making good on every promise we’ve made to our subscribers.
For example, on our very first day of publication, we alerted our subscribers to a biotech stock called Galapagos NV based on a recommendation from one of our experts.
Since then the stock has climbed as high as 213%, proving that we do deliver on such promises as:
- Providing “Access” to Our Experts: Private Briefing readers learned of the Galapagos profit opportunity because one of our financial editors had recommended it to the subscribers of his high-dollar trading service.
- Making Sure That You “Profit While You Learn:” Galapagos shares rose 103.5% in a bit more than six months after we recommended the shares to Private Briefing subscribers. From the outset, with updates along the way, we demonstrated to subscribers how to use big trends (such as those in the biotech sector) to identify major profit opportunities.
- Providing “Ahead-of-the-Curve Investment Advice and Recommendations: Months after we recommended Galapagos – and after it had run up as much as 103.5% (it moved much higher later) – institutional investors began taking big positions in Galapagos’ stock. And one of those institutions was Baker Bros. – a private equity player based on Madison Ave., that’s well-known for its biotech/healthcare savvy. In all, Baker Bros. purchased 6.48% of Galapagos’ outstanding shares.
- Generating Big Winners: In our first three years of publication, we’ve had 33 recommendations double or better, including a biotech stock that gained 629%. We’ve also had 11 recommendations end up as takeover or merger plays.
A: Absolutely not. In fact, a large group of our subscribers are quite sophisticated. For them it’s a value proposition since our recommendations have developed a reputation for generating big returns.
In fact, in the three-plus years since launching, Private Briefing has given readers 155 double- and triple-digit winners – that’s one big winner each and every week for over three years. Right now the portfolio contains winners worth 384%, 308%, 288%, 213%, 210%, 209%, 194% 188% and 175%… to name just a few.
A: With our daily discussions, Private Briefing embraces a “Profit While You Learn” philosophy that benefits investors who are brand new to the markets, or who are eager to build on their own knowledge of stocks, bonds, ETFs and the financial markets.
You see, we believe every investor has what it takes to be successful. That requires a strong, working knowledge of the financial markets and a willingness to operate independent of Wall Street.
Our “ahead-of-the-curve” approach allows investors to educate themselves about the markets while making winning trades.
A: Private Briefing is a unique advisory service that’s based on access, value and investor education. Each and every weekday, Executive Editor William Patalon III uses his unique position at Money Map Press to provide his subscribers with access to some of the best analysis, insights and “ahead-of-the curve” investment recommendations from such top Money Map Press experts as Shah Gilani, Michael Robinson, and Ernie Tremblay.